# Pharmasset

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharmasset

- Industry: Pharmaceuticals
- Headquarters: Princeton, US
- Website: www.pharmasset.com
- Total disclosed funding: $40M
- Latest round: Series D (Aug 10, 2004)
- Investors on record: 5

## About

Pharmasset, Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of viral infections, particularly hepatitis C and HIV.Founded in 1998 in Princeton, US, Pharmasset, Inc. specializes in antiviral drug development. The company underwent significant changes when it was acquired by Gilead Sciences, Inc. in January 2012 for USD 11.2 billion following a successful IPO in April 2007. The firm has concluded a total of 8 deals, with the most recent deal occurring on June 1, 2010.Pharmasset, Inc. focuses on developing novel antiviral medications, particularly for hepatitis C and HIV. Their key products, which have been integrated into Gilead's portfolio, include groundbreaking therapies that address critical unmet medical needs in treating chronic viral infections.In the most recent reporting year of 2011, Pharmasset, Inc. generated revenue of USD 897,000, with an EBITDA of USD -91,006,000.Pharmasset, Inc. plans to leverage its recent acquisition by Gilead Sciences to expand its product offerings and market presence. The company aims to enhance its portfolio by developing new antiviral therapies targeting hepatitis C and HIV, with anticipated releases in upcoming years. Recent funding from the acquisition will support these initiatives and allow Pharmasset to strengthen its market position across the United States and internationally.

## Funding rounds

- Series D, Aug 10, 2004, $40M — Burrill & Company, TVM Capital Life Science, CDIB BioScience Venture Management, MPM BioImpact, Lumira Ventures

## Investors

- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series D
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series D
- CDIB BioScience Venture Management (https://capitalatlas.ai/funds/cdib-bioscience-venture-management) — Series D
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series D
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series D